Significant Study of DSP107 Presentation at ASCO Annual Meeting
KAHR Bio is excited to announce an oral presentation concerning the compelling results of DSP107, a bi-specific 4-1BB T-cell engager, in an innovative study at an upcoming major oncology meeting. The study focuses on the exploration of this treatment in patients suffering from advanced colorectal cancer.
Key Findings in Metastatic Colorectal Cancer
DSP107 combined with atezolizumab has shown an impressive capacity to elicit anti-tumor effects in patients diagnosed with microsatellite stable colorectal cancer. Patients treated with this combination therapy demonstrated prolonged survival rates, even those with liver metastases. The results of this phase 2 study showcase a substantial enhancement in therapeutic outcomes for this difficult-to-treat cancer subtype.
Insights from KAHR Bio's Leadership
Dr. Yaron Pereg, CEO of KAHR Bio, expressed enthusiasm regarding the forthcoming data presentation at the ASCO Annual Meeting. He indicated that the significant implications of the study highlight the potential of the dual therapy in addressing an urgent unmet need in cancer treatment, especially for patients battling active liver metastases.
Details of the Oral Presentation
The details of this much-anticipated oral presentation are notable. The study titled "Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients" will be taking place at a key session focusing on gastrointestinal cancers. The presentation is set for a specific date where the audience will have the chance to hear from esteemed presenters regarding the updated findings from this innovative research.
Study Design and Objectives
This phase 2 study, which was an open-label, multi-center trial, focused on patients with advanced colorectal cancer. It uniquely investigated the safety and tolerability of DSP107 administered alongside atezolizumab. Moreover, the preliminary efficacy of this promising treatment was evaluated, laying groundwork for future studies.
Understanding DSP107 and its Mechanism
KAHR’s DSP107 is a pioneering immunotherapy that utilizes a unique mechanism of action to enhance the body’s immune response against cancer cells. By targeting the CD47 antigen, DSP107 effectively disrupts the camouflage that cancer cells employ to avoid detection by the immune system. This innovative approach not only activates innate immune responses but also mobilizes adaptive immunity, creating a dual-action treatment paradigm.
The Challenge of MSS-CRC
Microsatellite stable metastatic colorectal cancer presents distinct challenges in treatment. This subtype, characterized by its stability and lower mutational burden, often does not respond well to conventional immunotherapies. Standard treatment strategies have historically failed to yield significant benefits, prompting the need for innovative approaches like those being investigated with DSP107.
Overview of KAHR Bio
KAHR Bio is dedicated to developing state-of-the-art, dual-targeting fusion protein therapeutics aiming to activate both elements of the immune system. Founded on advanced scientific research, KAHR Bio focuses on expanding treatment options for numerous cancers by enhancing the body’s natural defenses. Their commitment to innovation is driving hope for better outcomes in cancer treatment.
Frequently Asked Questions
What is DSP107?
DSP107 is a first-in-class bi-specific 4-1BB T-cell engager designed to mobilize both innate and adaptive immune responses against solid tumors, particularly colorectal cancer.
What are the results of the Phase 2 study?
The results indicate improved survival rates and anti-tumor activity in patients with microsatellite stable metastatic colorectal cancer when treated with DSP107 and atezolizumab.
How does DSP107 work?
It targets CD47, facilitating immune recognition and activation against cancer cells, transforming them from a hidden threat into identifiable targets for the immune system.
What is the primary objective of the study?
The study primarily aims to assess the safety and tolerability of DSP107 in combination with atezolizumab among patients with advanced colorectal cancer.
What does KAHR Bio focus on?
KAHR Bio develops dual-targeting fusion protein therapeutics to enhance the immune system's response to various cancers, striving for innovative cancer treatment solutions.
